Rein Therapeutics Inc.
RNTX
$1.42
-$0.33-18.86%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -24.01% | 86.58% | -600.89% | 34.61% | -25.71% |
| Total Depreciation and Amortization | -- | -- | -- | -100.00% | -93.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.03% | -99.29% | 7,209.65% | 55.83% | 117.33% |
| Change in Net Operating Assets | 115.67% | 2.70% | -163.42% | 581.61% | -86.34% |
| Cash from Operations | -3.94% | -28.33% | -26.00% | 54.48% | -59.15% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 68.97% | 73,700.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -2.70% | -- |
| Cash from Financing | 538.48% | 73,700.00% | 100.22% | -102.44% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -100.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 68.62% | -12.99% | -12.83% | -143.19% | 287.35% |